date,title,source
Oct-23-18,"Report: Exploring Fundamental Drivers Behind Alder BioPharmaceuticals, DURECT, Mettler-Toledo International, Internap, Career Education, and Approach Resources  New Horizons, Emerging Trends, and Upcoming Developments",GlobeNewswire
Oct-25-18,DURECT Announces Abstracts on DUR-928 to be Presented at Upcoming Scientific Meetings,PR Newswire
Nov-01-18,DURECT Corporation Invites You to Join its Third Quarter 2018 Earnings Conference Call,PR Newswire
Nov-07-18,Durect: 3Q Earnings Snapshot,Associated Press
Nov-07-18,DURECT Corporation Announces Third Quarter 2018 Financial Results and Provides Corporate Update,PR Newswire
Nov-09-18,Edited Transcript of DRRX earnings conference call or presentation 7-Nov-18 9:30pm GMT,Thomson Reuters StreetEvents
Nov-13-18,Could DURECT Corporations (NASDAQ:DRRX) Investor Composition Influence The Stock Price?,Simply Wall St.
Nov-16-18,DRRX: Protocol Amendment Speeds DUR-928 Ph2 AH Trial. PERSERIS FDA Approval Adds New Revenue Stream,Zacks Small Cap Research
Nov-19-18,DURECT Announces Amendment to Accelerate Ongoing Phase 2a Trial of DUR-928 in Alcoholic Hepatitis (AH) by Allowing Dosing of Severe AH Patients in Parallel to Moderate AH Patients,PR Newswire
